Pancreatic cancer is one of the deadliest forms of cancer, largely because it’s so difficult to catch early. By the time it’s ...

Mainz Biomed has the exclusive rights to develop a test for early pancreatic cancer detection using Liquid Biosciences' biomarkers.

Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer Discovery Analysis Demonstrates Transformative Sensitivity of 95% ...

Mainz Biomed (MYNZ) announced it has entered into a License and Option Agreement with Liquid Biosciences to access a portfolio of novel mRNA ...

Discovery Analysis Demonstrates Transformative Sensitivity of 95% with Specificity of 98% for the Detection of Pancreatic ...